Alzheimer's Disease

The grounding supports a multifactorial etiology with both genetic and biological contributors. Early-onset disease can arise from dominant mutations in amyloid precursor protein or presenilin, and apolipoprotein E4 is associated with increased susceptibility. The literature also supports vascular contributions to cognitive impairment and dementia as relevant to cognitive decline in later life, though this is not specific to Alzheimer disease alone.

A central mechanism is imbalance between production and clearance of amyloid beta, especially Aβ42, leading to early amyloid accumulation. This is linked to downstream microgliosis, astrocytosis, and neurofibrillary tangle formation, with tau pathology reflected in the disease’s characteristic tangles and neuropil threads. The grounding also points to roles for phosphorylation, oxidative stress, neuronal plasticity, signal transduction, and immune-related processes in the disease biology.

Older age is a major risk factor, since the disease primarily occurs after age 60. Genetic risk is supported by apolipoprotein E4 and by pathogenic variants in amyloid precursor protein and presenilin. The supplied literature also indicates that vascular factors contribute to cognitive impairment and dementia in later life.

Diagnosis is generally based on clinical criteria showing insidious onset and progressive cognitive impairment, with neuropsychological testing used to support the diagnosis and assess course. Laboratory tests are not diagnostic for Alzheimer disease and are mainly used to exclude other causes of dementia. The grounding supports drug therapy and therapy as literature topics, but it does not provide enough detail to specify treatment classes beyond that.